paroxetine has been researched along with furafylline in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dansette, PM; Fontana, E; Poli, SM | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Chapple, S; Collins, C; Fairman, DA | 1 |
Reinen, J; Smit, M; Wenker, M | 1 |
1 review(s) available for paroxetine and furafylline
Article | Year |
---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
3 other study(ies) available for paroxetine and furafylline
Article | Year |
---|---|
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation?
Topics: Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Dihydralazine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; Humans; In Vitro Techniques; Kinetics; Microsomes, Liver; Models, Biological; NADP; Paroxetine; Pyrazines; Resveratrol; Stilbenes; Theophylline; Thiones; Thiophenes | 2007 |
Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.
Topics: Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Dihydralazine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Microsomes, Liver; Mifepristone; Paroxetine; Theophylline; Troleandomycin; Verapamil | 2018 |